scholarly journals Role of complete blood count, antioxidants, and total antioxidant capacity in the pathophysiology of acute coronary syndrome

2022 ◽  
Vol 4 (1) ◽  
pp. 37
Rumana Haque ◽  
Fahmida Binte Hafiz ◽  
Md. Ahsan Habib ◽  
Kazi Rafsan Radeen ◽  
Laila Noor Islam
2006 ◽  
Vol 86 (2) ◽  
pp. 304-309 ◽  
Mohamed Bedaiwy ◽  
Ashok Agarwal ◽  
Tamer M. Said ◽  
Jeffery M. Goldberg ◽  
Rakesh K. Sharma ◽  

1970 ◽  
Vol 5 (2) ◽  
pp. 89-90
Abdul Wadud Chowdhury ◽  
Amanullah Bin Siddiq ◽  
AEM Masharul Islam ◽  
Amitav Saha

Clopidogrel is an analogue of ticlopidine, used for reduction of atherosclerotic events in patients with acute coronary syndrome (ACS), stroke, peripheral arterial disease and for elective percutaneous coronary intervention (PCI). It selectively and irreversibly blocks ADP binding to platelets. Its primary side effect is bleeding. However potentially fatal types of haematological dyscrasia such as aplastic anaemia, neutropenia, thrombocytopenia, pancytopenia may be associated with clopidogrel therapy. A 50 years old diabetic, hypertensive lady with angina was started to treat with clopidogrel along with other anti-ischaemic and anti-hypertensive drugs. Subsequently the patient developed leucopenia and thrombocytopenia after starting of clopidogrel. Five days later her complete blood count returned to normal after withdrawal of both anti platelets. Aspirin was re-introduced with great precaution. Later repeat leucocyte and platelet count were found to be normal. At follow- up 1 month after discharge patient found asymptomatic with normal blood count. To the best of our knowledge, clopidogrel induced haematological dyscrasia was not reported earlier in our country. Key words: Acute coronary syndrome; percutaneous coronary intervention. DOI: 10.3329/uhj.v5i2.4563 University Heart Journal Vol.5(2) July 2009 pp.89-90

2004 ◽  
Vol 82 ◽  
pp. S195-S196 ◽  
M.A. Bedaiwy ◽  
A. Agarwal ◽  
T.M. Said ◽  
S. Worley ◽  
J. Thornton ◽  

2020 ◽  
Vol 10 (2) ◽  
pp. 110 ◽  
Leonardo Lorente ◽  
María M. Martín ◽  
Antonia Pérez-Cejas ◽  
Agustín F. González-Rivero ◽  
Pedro Abreu-González ◽  

Objective: Oxidation is involved in secondary brain injury after traumatic brain injury (TBI). Increased concentrations of total antioxidant capacity (TAC) in blood at the time of admission for TBI have been found in non-surviving patients. The main objective of this study was to determine the role of serum TAC levels at any time during the first week of TBI for the prediction of early mortality. Methods: Isolated (<10 points in non-cranial aspects of Injury Severity Score) and severe (<9 points in Glasgow Coma Scale) TBI patients were included. Serum TAC concentrations at days 1, 4, and 8 of TBI were determined. The end-point study was 30-day mortality. Results: Higher serum TAC levels at days 1 (p < 0.001), 4 (p < 0.001), and 8 (p = 0.002) of TBI were found in non-surviving (n = 34) than in surviving patients (n = 90). The area under curve (95% Confidence Interval) for prediction of 30-day mortality by serum TAC concentrations at days 1, 4, and 8 of TBI were 0.79 (0.71–0.86; p < 0.001), 0.87 (0.79–0.93; p < 0.001), and 0.76 (0.67–0.84; p = 0.006) respectively. Conclusions: The novelty of our study was the ability to predict 30-day mortality by serum TAC concentrations at any time during the first week of TBI.

Sign in / Sign up

Export Citation Format

Share Document